Best Practices and Research Advances in Thoracic Oncology: A Regional Series Eastern Europe/Baltic Course 2: Immunotherapy in Lung Cancer-Radiotherapy and Immunotherapy in NSCLC

Video Transcription

Video Summary

Haitham Nasrallah discusses the integration of immunotherapy with radiotherapy for non-small-cell lung cancer (NSCLC), emphasizing its potential to enhance outcomes significantly. Radiotherapy targets cancer cells and boosts the immune response, making it act like a tumor vaccine. Chemoradiotherapy followed by Dormanumab is now standard for inoperable stage 3 NSCLC per the PACIFIC study. However, combining immunotherapy early in treatment didn’t show benefits for stage 3. For stage 4, local therapy, including SBRT, improves survival for patients with oligoprogression, showcasing promising results in recent studies. Overall, integrating immunotherapy has a strong rationale and clinical support.

Asset Subtitle

Haitam Nasrallah, MD

Keywords

immunotherapy

radiotherapy

non-small-cell lung cancer

Dormanumab

oligoprogression